-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
DaVita delivered strong Q1 2026 results with adjusted EPS of $2.87, up 43.5% and well above the $2.33 consensus forecast, driven by higher reimbursement rates and continued aggressive share repurchases. Revenue increased 6.0% to $3.416B despite treatment volume headwinds, with U.S. dialysis revenue per treatment rising $17.45 to $417.59 reflecting higher reimbursement rates. The solid performance demonstrates operational resilience despite challenging normalized non-acquired treatment volume growth of just 0.1%. Management raised adjusted EPS guidance to $14.10-$15.20 from the prior $13.60-$15.00 range. Operating margin improved 50 basis points to 14.1% though compressed 140 basis points sequentially due to seasonal trends, while free cash flow surged to $140M from -$45M in the prior year quarter. The company maintained FCF guidance at $1.0B-$1.25B, supporting continued return of capital to shareholders, in our view.